Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Free Report) was the target of a large growth in short interest in the month of June. As of June 15th, there was short interest totaling 281,382 shares, a growth of 1,543.6% from the May 31st total of 17,120 shares. Approximately 6.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,102,038 shares, the days-to-cover ratio is currently 0.1 days.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Get Galmed Pharmaceuticals alerts:

View Our Latest Report on GLMD

Hedge Funds Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new position in Galmed Pharmaceuticals stock. Citadel Advisors LLC purchased a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Free Report) during the third quarter, according to its most recent filing with the SEC. The firm purchased 50,492 shares of the biopharmaceutical company’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 3.05% of Galmed Pharmaceuticals at the end of the most recent reporting period. 76.14% of the stock is owned by institutional investors and hedge funds.

Galmed Pharmaceuticals Price Performance

Shares of GLMD stock traded down $0.01 on Thursday, reaching $0.57. 109,980 shares of the stock were exchanged, compared to its average volume of 1,288,759. The stock has a market cap of $3.14 million, a PE ratio of -0.46 and a beta of 0.73. Galmed Pharmaceuticals has a one year low of $0.41 and a one year high of $2.34. The stock has a 50 day moving average price of $0.62 and a 200 day moving average price of $0.69.

About Galmed Pharmaceuticals

(Get Free Report)

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.

Featured Articles

• Five stocks we like better than Galmed Pharmaceuticals
• MDA Space Targets US Defense Market With $620M Acquisition
• Carnival’s Second Quarter: Is the Stock Still Complicated?
• Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
• Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.